NCT01843647 - Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2018

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG

Icotinib

Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.

DRUG

Chemotherapy

"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."

Trial Locations (1)

310022

RECRUITING

Zhejiang cancer hospital, Hangzhou